文献速递神经免疫

利妥昔单抗治疗视神经脊髓炎谱系疾病与MOG抗体病的长期有效性和安全性

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
PubMed 文献 · Neurology · 2022-08-31

本研究回顾性分析约翰霍普金斯视神经脊髓炎门诊111例AQP4-IgG阳性NMOSD和23例MOGAD患者,均接受至少1剂利妥昔单抗。利妥昔单抗启动后年化复发率在NMOSD(中位数1.1降至0,p<0.001)和MOGAD(中位数1.9降至0.3,p=0.002)均下降,但MOGAD复发风险更高(HR 2.8,95%CI 1.5-5.2,p=0.001),且感染和低丙种球蛋白血症需密切监测。

要点

  • 利妥昔单抗启动后NMOSD年化复发率中位数从1.1降至0,MOGAD从1.9降至0.3。
  • MOGAD患者利妥昔单抗治疗期间复发风险高于NMOSD(HR 2.8,95%CI 1.5-5.2)。
  • 13%患者发生需住院的感染,17%出现IgG低丙种球蛋白血症。

核心结论

  • 利妥昔单抗治疗与AQP4-IgG阳性NMOSD年化复发率降低相关,尤其在无治疗间隙和/或B细胞重建时。
  • MOGAD启动利妥昔单抗后虽观察到复发减少,但该关联似乎不如AQP4-IgG阳性NMOSD稳健。
  • 严重感染和低丙种球蛋白血症发生于显著比例的患者,突出密切监测感染并发症的必要性。

研究设计与样本

  • 回顾性病历审查,纳入约翰霍普金斯视神经脊髓炎门诊随访的AQP4-IgG阳性NMOSD或MOGAD患者,且接受至少1剂利妥昔单抗。
  • 共纳入111例NMOSD和23例MOGAD患者。

主要发现

  • NMOSD患者利妥昔单抗治疗中位 duration 3.7年(范围0.5-13.2年),MOGAD为2.1年(范围0.5-7.0年)。
  • NMOSD中位年化复发率治疗前1.1 vs 治疗后0(p<0.001);MOGAD治疗前1.9 vs 治疗后0.3(p=0.002)。
  • 利妥昔单抗治疗期间复发见于31例NMOSD(28%)和14例MOGAD(61%)。
  • NMOSD治疗失败(48次复发中的37次,77%)多发生于启动后初始6个月内(13次复发)或延迟/遗漏剂量和/或外周B细胞重建时(24次复发);MOGAD中这些情况占治疗失败比例较小(35次复发中的19次,54%)。
  • MOGAD患者利妥昔单抗治疗期间复发风险高于NMOSD(风险比2.8,95%CI 1.5-5.2,p=0.001)。

关键数值与推荐

  • 需住院的感染发生于13%患者,IgG低丙种球蛋白血症发生于17%患者。
  • IgG低丙种球蛋白血症发生前利妥昔单抗治疗中位 duration 5.4年(四分位距3.8-7.7年)。

临床怎么用

  • 利妥昔单抗治疗与AQP4-IgG阳性NMOSD年化复发率降低相关,尤其在无治疗间隙和/或B细胞重建时。
  • MOGAD启动利妥昔单抗后虽观察到复发减少,但该关联似乎不如AQP4-IgG阳性NMOSD稳健。
  • 严重感染和低丙种球蛋白血症发生于显著比例的患者,突出密切监测感染并发症的必要性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Rituximab is used widely for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG-associated disease (MOGAD); however, data regarding the effectiveness and safety of long-term rituximab use in these conditions are limited. In this study, we sought to evaluate long-term clinical outcomes in patients with aquaporin-4 IgG-seropositive (AQP4-IgG+) NMOSD and MOGAD treated with rituximab. METHODS: We performed a retrospective chart review of patients with AQP4-IgG+ NMOSD or MOGAD followed at the Johns Hopkins Neuromyelitis Optica Clinic and included patients who had received at least 1 dose of rituximab. RESULTS: We identified 111 patients with NMOSD and 23 patients with MOGAD who fulfilled the inclusion criteria. The median duration of rituximab treatment for the patients with NMOSD was 3.7 years (range: 0.5-13.2 years) and for the patients with MOGAD was 2.1 years (range: 0.5-7.0 years). The annualized relapse rate (ARR) decreased after rituximab initiation in both NMOSD (median ARR: pretreatment 1.1, posttreatment 0; p < 0.001) and MOGAD (median ARR: pretreatment 1.9, posttreatment 0.3; p = 0.002). Relapses on rituximab occurred in 31 patients with NMOSD (28%) and 14 patients with MOGAD (61%). The majority of NMOSD treatment failures (37/48 relapses; 77%) occurred either within the initial 6 months after starting rituximab (n = 13 relapses) or in the setting of delayed/missed rituximab doses and/or peripheral B-cell reconstitution (n = 24 relapses), whereas in MOGAD, these circumstances were present in a smaller proportion of treatment failures (19/35 relapses; 54%). The risk of relapse on rituximab was greater for patients with MOGAD compared with patients with NMOSD (hazard ratio: 2.8, 95% CI: 1.5-5.2, p = 0.001). Infections requiring hospitalization occurred in 13% and immunoglobulin G (IgG) hypogammaglobulinemia in 17% of patients. The median rituximab treatment duration before IgG hypogammaglobulinemia onset was 5.4 years (interquartile range: 3.8-7.7 years). DISCUSSION: Rituximab treatment is associated with the reduced annualized relapse rate in AQP4-IgG-seropositive NMOSD, especially in the absence of gaps in treatment and/or B-cell reconstitution. In MOGAD, although a reduction in relapses was observed after initiation of rituximab, this association appeared to be less robust than in AQP4-IgG-seropositive NMOSD. Severe infections and hypogammaglobulinemia occurred in a significant proportion of patients, highlighting the need for close monitoring of infectious complications. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that rituximab decreases the annualized relapse rate in AQP4-IgG-seropositive NMOSD and MOGAD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Barreras P, Vasileiou ES, Filippatou AG, et al. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease. Neurology. 2022. PMID: 36240094. doi:10.1212/WNL.0000000000201260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。